Breaking News

Tweet TWEET

Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer

  Anacor Pharmaceuticals Appoints Paul L. Berns as Chief Executive Officer

Business Wire

PALO ALTO, Calif. -- March 19, 2014

Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced that the Company’s
Board of Directors has appointed Paul L. Berns, Anacor’s Chairman of the Board
of Directors, to assume the role of President and Chief Executive Officer,
effective immediately. Mr. Berns succeeds David P. Perry who has served as
Anacor’s President and Chief Executive Officer since 2002.

Mr. Berns has over 20 years of industry experience as an executive in
biotechnology and pharmaceutical companies. He most recently served as the
President and Chief Executive Officer of Allos Therapeutics prior to its
acquisition by Spectrum Pharmaceuticals, Inc. in 2012.

“We appreciate David’s commitment to Anacor and the many contributions he has
made over the past 12 years to help build Anacor into the company it is
today,” said Paul Klingenstein, Chair of the Nominating and Governance
Committee of the Anacor Board. “We are delighted to have attracted a proven
leader of Paul’s capabilities to assume the role of CEO for the next phase of
Anacor’s growth. Having served as Chairman, Paul has a deep knowledge of
Anacor’s management team, strategy, partners and development pipeline, thus
enabling a smooth transition. Additionally, Paul’s significant commercial and
product development experience, combined with his strategic and business
development expertise, makes him ideally suited to lead Anacor as we seek to
achieve our goals.”

“I am honored to lead Anacor at a time when it has a number of promising
product candidates,” commented Mr. Berns. “We await action by the FDA this
summer on our Kerydin NDA and look forward to launching pivotal studies of
AN2728 in mild-to-moderate atopic dermatitis patients. We are encouraged by
the progress of our lead programs and are confident in our financial strength
and commercialization prospects. I look forward to working closely with the
Company’s talented team as we continue to make progress on the next steps for
Kerydin and the ongoing development of AN2728.”

About Paul L. Berns

Mr. Berns has served as a member of our board since 2012. From March 2006 to
August 2012, Mr. Berns served as President and Chief Executive Officer, and
member of the Board of Directors, of Allos Therapeutics, Inc., which was
acquired by Spectrum Pharmaceuticals, Inc. in August 2012. From June 2002 to
July 2005, Mr. Berns was president, Chief Executive Officer and a director of
Bone Care International, Inc., a specialty pharmaceutical company that was
acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served
as Vice President and General Manager of the Immunology, Oncology and Pain
Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he
served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and, from
1990 to 2000, Mr. Berns held various positions, including senior management
roles, at Bristol-Myers Squibb Company. Mr. Berns has been a director of Jazz
Pharmaceuticals, PLC since 2010 and of XenoPort, Inc. since 2005. Mr. Berns
received a B.S. in Economics from the University of Wisconsin.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company focused on discovering, developing and
commercializing novel small-molecule therapeutics derived from its boron
chemistry platform. Anacor has discovered eight compounds that are currently
in development. Its two lead product candidates are topically administered
dermatologic compounds — Kerydin, an antifungal for the treatment of
onychomycosis, and AN2728, an anti-inflammatory PDE-4 inhibitor for the
treatment of atopic dermatitis and psoriasis. In addition to its two lead
programs, Anacor has discovered three other wholly-owned clinical product
candidates — AN2718 and AN2898, which are backup compounds to Kerydin and
AN2728, respectively, and AN3365, an antibiotic for the treatment of
infections caused by Gram-negative bacteria. Anacor has also discovered three
other compounds that have been out-licensed for further development — one is
licensed to Eli Lilly and Company for the treatment of an animal health
indication, the second compound, AN5568, also referred to as SCYX-7158, is
licensed to Drugs for Neglected Diseases initiative, or DNDi, for human
African trypanosomiasis (HAT, or sleeping sickness) and the third compound is
licensed to GlaxoSmithKline, LLC for development in tuberculosis. Anacor also
has a pipeline of other internally discovered topical and systemic boron-based
compounds in development. For more information, visit http://www.anacor.com.

Forward-Looking Statements

This release contains forward-looking statements, including statements
regarding our transition to new leadership of the Company, clinical plans and
financial projections. Our actual results may differ materially from those
indicated in these forward-looking statements due to risks and uncertainties,
including recent management changes; the next steps for the potential approval
and commercialization of Kerydin; the plans for AN2728; risks relating to
patient accrual and execution on clinical plans; the potential for success of
Kerydin and our AN2728 compound; the size of the markets in onychomycosis,
atopic dermatitis and psoriasis; financial projections related to our cash
balance and use of cash as well as our ability to fund operations as currently
conducted; and other matters that are described in Anacor's Annual Report on
Form 10-K for the year ended December 31, 2013 filed with the Securities and
Exchange Commission on March 17, 2014, including the risk factors set forth in
that filing. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this release
and we undertake no obligation to update any forward-looking statement in this
press release.

Contact:

Anacor Pharmaceuticals
Geoff Parker, 650-543-7516
Senior Vice President and Chief Financial Officer
or
DeDe Sheel, 650-543-7575
Senior Director, Investor Relations and Corporate Communications
 
Press spacebar to pause and continue. Press esc to stop.